COVID-19 Vaccines Clinical Trial
Official title:
Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized Adults - Phase I Study
This will be a phase I, single-center trial, including a total of 30 participants in two cohorts. Cohort 1 (n=6): Healthy male or female adults aged 18 - ≤ 60 previously primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen. Cohort 2 (n=24): Healthy male or female adults aged 18 - ≤ 60 primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen and subsequently booster immunized with any EU marketed mRNA vaccine Both cohorts will be assigned to inhaled vaccination with MVA-SARS-2-ST
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05918939 -
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
|
Early Phase 1 | |
Active, not recruiting |
NCT06272253 -
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
|
Early Phase 1 | |
Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
Recruiting |
NCT05185817 -
Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients
|
Phase 2 | |
Not yet recruiting |
NCT04876885 -
The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations
|
N/A | |
Completed |
NCT05373459 -
Effect of a Third COVID-19 Booster Among Health Care Workers
|
||
Active, not recruiting |
NCT05571657 -
COVID-19 Booster Dose Reminder/Recall for Adolescents
|
N/A | |
Completed |
NCT04888793 -
Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
|
||
Completed |
NCT04881396 -
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
|
||
Recruiting |
NCT04871165 -
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
|
||
Active, not recruiting |
NCT05293665 -
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
|
Phase 3 | |
Active, not recruiting |
NCT05405283 -
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
|
Phase 3 | |
Recruiting |
NCT05508477 -
UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)
|
Phase 3 | |
Recruiting |
NCT05471635 -
Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
|
||
Recruiting |
NCT06282692 -
INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old
|
Phase 3 | |
Completed |
NCT05406908 -
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
|
Phase 4 | |
Recruiting |
NCT04895007 -
Comparative Evaluation of Covid-19 Vaccines Response
|
||
Recruiting |
NCT05831826 -
Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
|
||
Recruiting |
NCT05096260 -
Getting to Yes, Michigan! (G2YMI)
|
N/A | |
Completed |
NCT04962906 -
Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes
|
Phase 2 |